UBS lowered the firm’s price target on Colgate-Palmolive (CL) to $90 from $92 and keeps a Buy rating on the shares. Colgate-Palmolive delivered a Q4 sales beat despite weaker organic revenue and gross margin, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate-Palmolive price target lowered to $87 from $88 at JPMorgan
- Colgate-Palmolive price target lowered to $94 from $100 at Evercore ISI
- Colgate-Palmolive price target lowered to $87 from $96 at Morgan Stanley
- Colgate-Palmolive price target lowered to $95 from $105 at Citi
- Colgate-Palmolive price target lowered to $77 from $80 at Wells Fargo